Skip to content

Three-dimensional computed tomography reconstruction in minimally invasive segmentectomy: a prospective randomized controlled trial

Three-dimensional computed tomography reconstruction in minimally invasive segmentectomy: a prospective randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050029
Enrollment
Unknown
Registered
2021-08-16
Start date
2021-08-16
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Intervention Group:Three-dimensional reconstruction of preoperative chest enhanced CT images
Control Group:Enhanced CT images of the chest before surgery

Sponsors

The Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years old; 2. The preoperative clinical diagnosis was peripheral non-small cell lung cancer, and CT showed that the maximum diameter of the tumor was <=2cm; 3. Minimally invasive segmentectomy in Qingdao University Affiliated Hospital; 4. Preoperative clinical evaluation of minimally invasive segmentectomy can achieve R0 resection; 5. No distant metastasis in preoperative clinical assessment; 6. Preoperative clinical evaluation of cardiopulmonary function and liver and kidney function can tolerate surgery; 7. American Society of Anesthesiologists (ASA) score I-III; 8. No chemotherapy, radiotherapy, targeted therapy or immunotherapy before surgery; 9. It is understandable to cooperate with the research and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. History of previous thoracic trauma or ipsilateral thoracic surgery; 2. Suffering from serious illnesses, and should not be included in the study after evaluation by the investigator; 3. Suffering from mental illness and poor compliance; 4. Inability to tolerate enhanced computed tomography; 5. The postoperative pathological diagnosis was small cell lung cancer.

Design outcomes

Primary

MeasureTime frame
Incidence of change of surgical plan;Intraoperative blood loss;

Secondary

MeasureTime frame
Incidence of postoperative complications;Postoperative 30-day mortality;Length of stay in hospital;Number of lymph node dissected;Chest tube duration;Overall survival;Disease free survival;operation time;

Countries

China

Contacts

Public ContactJiao Wenjie

The Affiliated Hospital of Qingdao University

jiaowj@qduhospital.cn+86 18661806899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026